It is encouraging that the addition of TGFBR1 inhibitors can restore the cytotoxic phenotype of NK cells, which highlights the potential of TGFBR1 and the TGF-β pathway in cancer treatment [122]. The gene discussed is TGFB1; the disease is cancer.